DNLI — Denali Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1714899 ·
Last close
$19.38
Market Cap
$3.08B
52W High
$23.46
52W Low
$17.71
ADV30
1,734,409
Next earnings
2026-05-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -137,357,000 | -128,447,000 | 1,266,023,000 | 387,626,000 | 339,925,000 |
| Dec 2025 | 0 | — | -137,365,000 | -128,549,000 | 1,144,854,000 | 205,326,000 | 131,093,000 |
| Sep 2025 | 0 | — | -137,434,000 | -126,902,000 | 1,055,621,000 | 90,963,000 | 129,424,000 |
| Jun 2025 | 0 | — | -134,963,000 | -124,119,000 | 1,166,241,000 | 141,207,000 | 139,188,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-412,600,000
Investing CF
$255,281,000
Financing CF
$189,216,000
CapEx
$-15,972,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.97
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,051,524,000
Inventory
—
Receivables
$2,177,000
ST Investments
$662,553,000
EBIT TTM
$-555,342,000
Pretax Income TTM
$-512,438,000
Interest Exp TTM
—
Analysts
14
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -555,342,000 | -512,540,000 | 1,144,854,000 | 131,093,000 | — | -412,600,000 |
| Dec 2024 | 0 | -501,878,000 | -422,773,000 | 1,374,180,000 | 144,496,000 | — | -347,694,000 |
| Dec 2023 | 330,531,000 | -196,699,000 | -145,224,000 | 1,153,917,000 | 122,963,000 | — | -357,991,000 |
| Dec 2022 | 108,463,000 | -340,744,000 | -325,991,000 | 1,460,242,000 | 417,812,000 | — | -244,716,000 |
TTM Snapshot
Revenues TTM
$10,111,000
NetIncome TTM
$-394,432,000
OpCashFlow TTM
$0
Assets (Latest)
$1,374,180,000
Forward EPS
$-2.49
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BEAM | Beam Therapeutics Inc. | $3.06B | $29.79 | — |
| RLAY | Relay Therapeutics, Inc. | $3.04B | $14.17 | — |
| TARS | Tarsus Pharmaceuticals, Inc. | $2.63B | $61.16 | — |
| TWST | Twist Bioscience Corp | $4.04B | $64.87 | — |
| ADPT | Adaptive Biotechnologies Corp | $2.26B | $14.13 | — |
News headlines (Yahoo Finance, 1h cache)
Denali Therapeutics' Focus Shifts to Other Pipeline Assets After Phase 2b Study Failure, Morgan Stanley Says
2026-05-26 15:29 · Yahoo
Stocks Settle Higher on Iran Peace Hopes and Tech Strength
2026-05-22 20:34 · Yahoo
Biogen Faces Trial Setbacks And Probes That Reframe Neuro Pipeline Risks
2026-05-22 20:15 · Yahoo
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
2026-05-22 16:14 · Yahoo
Stocks Climb on US-Iran Peace Hopes and Strength in Chipmakers
2026-05-22 15:20 · Yahoo
Stocks Supported by US-Iran Peace Deal Optimism
2026-05-22 14:13 · Yahoo
Parkinson’s drug from Biogen, Denali comes up short
2026-05-22 10:46 · Yahoo
BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial
2026-05-21 23:03 · Yahoo
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
2026-05-21 22:00 · Yahoo
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval
2026-05-18 18:43 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.